InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions
June 14 2022 - 7:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the research, development,
manufacturing and commercialization of rare cannabinoids, today
announced that a peer-reviewed scientific study entitled “Effects
of Rare Phytocannabinoids on the Endocannabinoid System of Human
Keratinocytes” has been published in the International Journal of
Molecular Sciences. The study, in collaboration with Dr. Mauro
Maccarrone, Professor and Chair of Biochemistry at the Department
of Biotechnological and Applied Clinical Sciences, University of
L’Aquila, Italy, highlights the biological activity of
tetrahydrocannabivarin (“THCV”), cannabichromene (“CBC”) and other
rare cannabinoids and their potential role in addressing various
skin conditions.
In the peer-reviewed study, researchers analyzed
the effects of rare cannabinoids THCV, CBC, cannabigerol (“CBG”)
and cannabigerolic acid (“CBGA”) on the major endocannabinoid
system elements in skin cells. Using a widely recognized in vitro
model of human keratinocytes, researchers studied how these
cannabinoids interacted with several receptors including
cannabinoid receptors and other endocannabinoid system components.
In summary, each cannabinoid had distinct biological activity via
the endocannabinoid system. In particular, THCV was shown to
perform as a cannabinoid receptor 1 (“CB1”) antagonist and have a
high affinity for the human transient receptor potential vanilloid
1 (“TRPV1”), which is involved in skin sensation, as did CBC albeit
to a lesser extent. The results from the study support additional
research of these rare cannabinoids for their potential effect on
skin conditions.
“This study represents the first systematic
analysis of the effects of the rare cannabinoids THCV, CBC, CBGA
and CBG on the major endocannabinoid system elements using human
keratinocytes. These initial observations should be considered when
exploring the therapeutic potential of rare cannabinoids for the
treatment of human skin disease,” said InMed’s scientific advisor,
Dr. Mauro Maccarrone.
“This peer-reviewed study provides important
scientific research investigating the distinctly different
physiological effects of rare cannabinoids,” said Dr. Eric Hsu,
Senior VP, Preclinical Research and Development. “As we continue to
expand our portfolio of rare cannabinoids, including THCV and CBC,
evidence-based research is imperative to improving our
understanding of their biological activity. There is growing
interest in the potential benefits of rare cannabinoids and this
study represents InMed’s commitment to contributing to the body of
research of rare cannabinoids.”
The journal article can be accessed here:
https://www.mdpi.com/1422-0067/23/10/5430
InMed’s subsidiary, BayMedica LLC (BayMedica”), manufactures
commercial-scale, high purity, bioidentical rare cannabinoids for
the health and wellness industry. BayMedica launched B2B sales of
THCV in June 2020, adding to its portfolio which also includes
cannabidivarin (“CBDV”), cannabicitran (“CBT”) and CBC.
About InMed: InMed
Pharmaceuticals is a global leader in the research, development,
manufacturing and commercialization of rare cannabinoids. Together
with its subsidiary BayMedica LLC, the Company has unparalleled
cannabinoid manufacturing capabilities to serve a spectrum of
consumer markets, including pharmaceutical and health and wellness.
InMed is also a clinical-stage company developing a pipeline of
rare cannabinoid therapeutics and dedicated to delivering new
treatment alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com and www.baymedica.com.
Investor Contact: Colin ClancyVice President,
Investor Relations & Corporate CommunicationsT:
+1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: a peer-reviewed scientific study
entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid
System of Human Keratinocytes highlighting the biological activity
of THCV, CBC and other rare cannabinoids and their potential role
in addressing various skin conditions; using a widely recognized in
vitro model of human keratinocytes, researchers studied how these
cannabinoids interacted with several receptors including
cannabinoid receptors and other endocannabinoid system components;
each cannabinoid had distinct biological activity via the
endocannabinoid system; THCV is shown to perform as a cannabinoid
receptor 1 (“CB1”) antagonist and have a high affinity for the
human transient receptor potential vanilloid 1 (“TRPV1”), which is
involved in skin sensation; results from the study support
additional research of these rare cannabinoids for their potential
effect on skin conditions; study provides important scientific
research investigating the distinctly different physiological
effects of rare cannabinoids; growing interest in the potential
benefits of rare cannabinoids; being a global leader in the
research, development, manufacturing and development of rare
cannabinoids; and delivering new treatment alternatives to patients
that may benefit from cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous assumptions
regarding, among other things: the ability to obtain all necessary
regulatory approvals on a timely basis, or at all; and continued
economic and market stability. While InMed considers these
assumptions to be reasonable, these assumptions are inherently
subject to significant business, economic, competitive, market and
social uncertainties and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s Annual Report on Form 10-K and other
filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024